Everything below concerns PPARδ agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
They are non-essential contributors that facilitate the replacement of type I collagen to type III collagen. Wound retraction occurs in this stage, in which the proliferation factors TGFβ1 and VEGF-A, mainly produced by dermal macrophages, are reduced to facilitate the process. There will be a gradual reduction in an inflammatory response in the wound through the secretion of proliferation factors. Anti-inflammatory dermal macrophages are also activated to alleviate the inflammation as healing reaches completion. They express IL-10 and IL-1Ra to suppress inflammation.
In spite of the preponderance of the "tricolor" party in the provisional government, so long as the voice of France had not spoken, the socialists, supported by the Parisian proletariat, had exercised an influence on policy disproportionate to their relative numbers. By the decree of 24 February, the provisional government had solemnly accepted the principle of the "right to work", and decided to establish "National Workshops" for the unemployed; at the same time, a sort of industrial parliament was established at the Luxembourg Palace, under the presidency of Louis Blanc, with the object of preparing a scheme for the organization of labor; and, lastly, by the decree of 8 March, the property qualification for enrolment in the National Guard had been abolished and the workmen were supplied with arms. The socialists thus formed a sort of state-within-a-state, complete with a government and an armed force.
Aldi Süd, Lidl and Asda join Sainsbury's and Tesco in cutting the retail price of milk. Several thousand workers with the Environment Agency belonging to the UNISON trade union begin a three-day strike over pay and conditions. Coronation of Charles III and Camilla Official chinaware manufactured by the Royal Collection Trust, in Stoke-on-Trent is unveiled. Media, including BBC News, report that Sarah, Duchess of York has not been invited to the coronation. Some details of the Coronation Concert are revealed, with acts including Katy Perry, Lionel Richie and Take That confirmed as part of the line-up. 15 April The SNP's National Executive Committee orders a review of the party's transparency and governance. Merseyside Police say that 118 people have been arrested at Aintree Racecourse after protestors delay the start of the 2023 Grand National. The race, which is delayed by 14 minutes, is won by Corach Rambler, ridden by Derek Fox. 16 April – The building of all new smart motorways is cancelled over cost and safety concerns. 17 April The 2023 World Snooker Championship is disrupted by a protestor from Just Stop Oil who climbs onto the snooker table during a match between Robert Milkins and Joe Perry and pours orange powder over it. Two people are later arrested by South Yorkshire Police. The Parliamentary Commissioner for Standards is to investigate Prime Minister Rishi Sunak over a possible failure to declare an interest over a childcare company in which his wife has shares.
1292–1319: Dame Péronelle, French herbalist. 13th century Shen Yu Hsiu, Chinese chemist. fl. 1300 Gilette de Narbonne, French physician. Giovanni Boccaccio wrote of her in ‘’The Decameron’’, calling her ‘Donna Medica’; Alfred Duru and Henri Chivot wrote a comic opera about her called Gillette de Narbonne. f. 1307 Trotta da Toya, Napolitan physician. fl. 1308 Francisca di Vestis, Napolian physician. fl. 1309 Maria Gallicia, licensed surgeon. fl. 1313–1325: Ameline la Miresse, French physician. fl. 1318–1324: Adelmota of Carrara was a physician in Padua, Italy. fl. 1318: Alessandra Giliani, Italian anatomist. 1320: Raymunda da Taberna, licensed Napolitan surgeon. fl. 1322: Fava of Manosque, French-Jewish physician. fl. 1322: Jacobina Félicie, Italian physician. fl. 1326: Sara de Sancto Aegidio, French physician. fl. 1326: Sarah de St Giles, French-Jewish physician and medical teacher. fl. 1333: Constanza, Italian surgeon, mentioned in Pope Sixtus IV edict regarding physicians and surgeons. fl. 1333: Francisca da Romana, Napolitan physician. fl. 1333: Isabella da Ocre, Napolitan surgeon. fl. 1333: Lauretta Ponte da Saracena Calabria, Napolitan physician. fl. 1333: Margarita da Venosa, licensed Napolitan surgeon, who studied at the University of Salerno She was considered a noteworthy practitioner and counted Ladislaus, king of Naples, as a patient. fl. 1333: Maria Incarnata, Italian surgeon, mentioned in Pope Sixtus IV edict regarding physicians and surgeons. fl. 1333: Sibyl of Benevento, Napolitan physician specializing in the plague buboes fl.
Sources: en.wikipedia.org
joint involvement, designating the metacarpophalangeal joints, proximal interphalangeal joints, the interphalangeal joint of the thumb, second through fifth metatarsophalangeal joint and wrist as small joints, and shoulders, elbows, hip joints, knees, and ankles as large joints: Involvement of 1 large joint gives 0 points Involvement of 2–10 large joints gives 1 point Involvement of 1–3 small joints (with or without involvement of large joints) gives 2 points Involvement of 4–10 small joints (with or without involvement of large joints) gives 3 points Involvement of more than 10 joints (with involvement of at least 1 small joint) gives 5 points serological parameters – including the rheumatoid factor as well as ACPA – "ACPA" stands for "anti-citrullinated protein antibody": Negative RF and negative ACPA gives 0 points Low-positive RF or low-positive ACPA gives 2 points High-positive RF or high-positive ACPA gives 3 points acute phase reactants: 1 point for elevated erythrocyte sedimentation rate, ESR, or elevated CRP value (c-reactive protein) duration of arthritis: 1 point for symptoms lasting six weeks or longer The new criteria incorporate the growing understanding of and the advances in diagnosing and treating RA. In the "new" criteria, serology and autoimmune diagnostics carry major weight, as ACPA detection is appropriate to diagnose the disease in an early state, before joints destructions occur. Destruction of the joints seen in radiological images was a significant point in the ACR criteria from 1987.
York Chow, the health secretary of Hong Kong, said he thought animal feeds might be the source of the contamination and announced that the Hong Kong Centre for Food Safety would henceforward be testing all mainland Chinese pork, farmed fish, animal feed, chicken meat, eggs, and offal products for melamine. As of July 2010, Chinese authorities were still reporting some seizures of melamine-contaminated dairy product in some provinces, though it was unclear whether these new contaminations constituted wholly new adulterations or were the result of illegal reuse of material from the 2008 adulterations. On characterization and treatment of urinary stones in affected infants, The New England Journal of Medicine printed an editorial in March 2009, along with reports on cases from Beijing, Hong Kong and Taipei. Urinary calculi specimens were collected from 15 cases treated in Beijing and were analyzed as unknown objects for their components at Beijing Institute of Microchemistry using infrared spectroscopy, nuclear magnetic resonance, and high performance liquid chromatography. The result of the analysis showed that the calculus was composed of melamine and uric acid, and the molecular ratio of uric acid to melamine was around 2:1.
== IGF-binding proteins == IGF-1 and IGF-2 are regulated by a family of proteins known as the IGF-binding proteins. These proteins help to modulate IGF action in complex ways that involve both inhibiting IGF action by preventing binding to the IGF-1 receptor as well as promoting IGF action possibly through aiding in delivery to the receptor and increasing IGF half-life. Currently, there are seven characterized IGF Binding Proteins (IGFBP1 to IGFBP7). There is currently significant data suggesting that IGFBPs play important roles in addition to their ability to regulate IGFs. IGF-1 and IGFBP-3 are GH dependent, whereas IGFBP-1 is insulin regulated. IGFBP-1 production from the liver is significantly elevated during insulinopenia while serum levels of bioactive IGF-1 is increased by insulin.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.